Anzeige
Mehr »
Login
Montag, 23.09.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Die FED senkt die Zinsen, Gold explodiert: Die eine Aktie, die sie alle überstrahlen könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Actusnews Wire
156 Leser
Artikel bewerten:
(1)

DON'T NOD reports on activity in the first half of 2024

Paris, September 23, 2024 - DON'T NOD, an independent French studio that creates, develops, and publishes video games, today reports on its first-half 2024 activity and roadmap, following on from the announcements made at the presentation of the 2023 full-year results and considering its financial performance in H1 2024.

Oskar Guilbert, Chairman and Chief Executive Officer said: "We are obviously disappointed by our recent performance in an extremely competitive and selective market. Despite an excellent critical reception, Jusant and Banishers: Ghosts of new Eden unfortunately did not achieve the commercial results we had hoped for, resulting in a deterioration in our 2024 half-year results and leading us to consider all possible options regarding our roadmap."

H1 2024[1] activity

Consolidated figues in €000, unauditedH1 2023H1 2024
Revenues2,6631,871
- incl. development2,05019
- incl. sales6131,852
Capitalized production[2]13,80012,710
Total operating revenues[3]16,46314,581


For the first half of 2024, DON'T NOD posted an 11% decline in operating revenues to €14.6 million, versus €16.5 million in H1 2023. This increase reflects:

  • an increase in sales (+€1.2 million), mainly driven by the back catalog (Vampyr and the Life is Strange license) and the contribution of Jusant (released at the end of October 2024) and Banishers: Ghosts of new Eden (released mid-February 2024), which performed well below expectations;
  • development revenues down (-€2.0 million), reflecting the completed development of Banishers: Ghosts of new Eden;
  • a reduction in capitalized production (-€1.1 million), resulting from the temporary suspension of 2 production lines.

These operating revenues will not cover operating expenses (excluding depreciation, amortization and provisions), meaning that operating EBITDA[4] is expected to show a loss (of around -€1.0 million) for the first half of 2024.

Performance enhancement measures

In this context of underperformance, DON'T NOD has decided to:

- Partially write down, in the amount of €24 million, the assets of Jusant and Banishers: Ghost of New Eden, given the inability to demonstrate future cash flows commensurate with the value of these assets;

- Focus its efforts and resources on the Intellectual Property in production offering the highest potential return on investment in the short (and medium) term, with:

  • Lost Records: Bloom & Rage, the first game developed by the Montreal studio and the creative minds behind the Life is Strange franchise. Played for the first time by the press at Gamescom, Lost Records: Bloom & Rage has received a particularly positive reception, and its new trailer has engaged millions of players on our social networks (first episode scheduled for February 2025 and the second for March 2025). At the same time, discussions are continuing with industry leaders to secure economic benefits;
  • Two in-house projects (P10 and P14) scheduled for release before the end of 2027, with titles yet to be announced. In order to bolster sales potential and increase partnership opportunities with industry leaders, project design has been refocused to reach a wider audience, which involves scrapping certain developments (P10);
  • Support for two external publishing projects (due for release in 2025), which will contribute to revenues from next year onwards.

- Temporarily pausing two projects in the design phase in Paris (P12 and P13), entailing a write-down of €7.6 million. This decision will enable us to prioritize resources and maximize the chances of success of the titles with the greatest potential at present.

Taken together, these decisions will lead to an impairment of fixed assets of €31.6 million, and to the recognition of a non-recurring expense of around €8.5 million. These factors will have a significant impact on 2024 half-year results, with no cash impact (cash position expected to be €45.5 million at the end of June 2024).

DON'T NOD is also exploring other options that could be implemented as soon as possible to secure its operations and enhance value creation. The purpose of this review is to give DON'T NOD the ability to compete more successfully in a constantly evolving industry, and to respond effectively to the expectations of players and partners, while continuing to offer innovative, high-quality experiences.

About DON'T NOD

DON'T NOD is an independent French publisher and developer with studios in Paris and Montréal creating original narrative games in the adventure (Life is StrangeTM, Tell Me WhyTM, Twin MirrorTM), RPG (VampyrTM, Banishers: Ghosts of New EdenTM), and action (Remember MeTM) genres. The studio is internationally renowned for unique narrative experiences with engaging stories and characters and has worked with industry leading publishers: Square Enix, Microsoft, Bandai Namco Entertainment, Focus Entertainment and Capcom. DON'T NOD creates and publishes its own IPs developed in-house such as Harmony: The Fall of Reverie TM, Jusant TM and Lost Records: Bloom & Rage TM, as well as using its knowledge and experience to collaborate with third-party developers whose editorial visions parallel the company's own.

Step into the studio's immersive and innovative universe at dont-nod.com

DON'T NOD (ISIN code: FR0013331212 - ALDNE) is listed on Euronext Growth Paris

DON'T NOD
Oskar GUILBERT
Chief Executive Officer

Agathe MONNERET
Chief Financial Officer
invest@dont-nod.com
ACTUS finance & communication
Corinne PUISSANT
Analyst/Investor relations
Tel.: 33 (0)1 53 67 36 77 - dontnod@actus.fr

Amaury DUGAST
Press relations
Tel.: 33 (0)1 53 67 36 74 - adugast@actus.fr

[1] All figures relating to the consolidated financial statements at June 30, 2024 in this press release are currently under limited review by our Statutory Auditors.

[2] Costs incurred on co-produced and self-published games until release

[3] Revenues + capitalized production

[4] Operating income + Depreciation and amortization charges & provisions net of reversals + tax credits

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: lJlraJVqZGfJx21qaZ6XaGWYl5ySmJSZa2ibmpJxlcucbG+UmWxkZpXIZnFonWhv
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-87839-2024_09_23_cp_dne_activite_s12024_vuk_vdef.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2024 Actusnews Wire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.